IN THE UNITED STATES PATENT AND TRADEMARK OFFICE									
	•	RC-28	301-138					والمواسدة	,
/ ? ¿. ,	kt.	C#	M#)	74	
Aleardo KOVERCH NOV 2 3 2007 E TC/A.U.	4	133							
\ 1	iner: V	Vebb							•
Filed: June 14, 2005	oate: N	lovem	ber 23, 20	07					
Title: USE OF L-CARNITINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES									
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450									
Sir: RESPONSE/AMENDMENT/LETTER									
This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.									
☐ Correspondence Address Indication F	Form	Attac	hed.						
Fees are attached as calculated below: Total effective claims after amendment 0 m previously paid for 20 (at least 20) = 0		ghest \$50.00	number)	\$0	.00 (120	02)/\$0.00	(2202)	\$	
Independent claims after amendment previously paid for 3 (at least 3) = 0		ghest \$210.0	number 00	\$0	.00 (120	01)/\$0.00	(2201)	\$	
If proper multiple dependent claims now added for fir	st time	, (igno	re imprope						
Thre F	One M wo Mor ee Mon Four Mo	Month oth Ex oth Ext onth E	ever the fili Extension tensions \$ ensions \$ xtensions ensions \$2	ing date \$120.00 460.00 (1050.00 \$1640.0	of this (1251)/ 1252)/\$ (1253/\$ 0 (1254	230.00 (2 525.00 (2 /\$820.00	2251) 2252) 2253) (2254)		
Terminal disclaimer enclosed, add				\$130.00	(1814)	/ \$65.00	(2814)	\$	
☐ Applicant claims "small entity" status. ☐ State	ement f	filed h	erewith						
Rule 56 Information Disclosure Statement Filing Fee					\$	180.00 (1806)	\$	0.00
Assignment Recording Fee						\$40.00 (8021)	\$	0.00
Other: Response to Requirement for Restriction; Co	py of P	TO/SI	3/08A filed	June 14	, 2005			\$	0.00
COPEDIT CARD DAVMENT FORM A	TT A ^					TOTA	AL FEE	\$	0.00
CREDIT CARD PAYMENT FORM A							/ \ C1		
The Commissioner is hereby authorized to charge any <u>deficiency</u> , or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.									
901 North Glebe Road, 11th Floor Arlington, Virginia 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100 ARC:eaw		y: Art	ANDERHY hur R. Cra		eg. No.	25,327			

#1274397 V1 - 2801-138.Fs



In re Patent Application of

Aleardo KOVERCH Atty. Ref.: 2801-138; Confirmation No. 7287

Appl. No. 10/538,868 TC/A.U. 4133

Filed: June 14, 2005 Examiner: Webb

For: USE OF L-CARNITINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

November 23, 2007

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE TO REQUIREMENT FOR RESTRICTION

Responsive to the Official Action of November 1, 2007 and the requirement for restriction presented in it, applicant elects the subject matter of claims 1, 3-5, 10 and 11, Group I, directed to reducing deaths caused by acute myocardial infarction by administering L-carnitine. This response is made with traverse.

Please examine the elected claims on the merits taking into account the documents cited in the International Search Report in the underlying PCT application as listed on the form (copy attached) and the Information Disclosure Statement filed June 14, 2005.

Aleardo KOVERCH
Appl. No. 10/538,868
November 23, 2007

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Arthur R. Crawford Reg. No. 25,327

ARC:eaw 901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100